Ignite Creation Date:
2025-12-25 @ 2:18 AM
Ignite Modification Date:
2026-02-22 @ 12:47 AM
Study NCT ID:
NCT03748134
Status:
COMPLETED
Last Update Posted:
2023-10-24
First Post:
2018-11-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Esophageal Squamous Cell Carcinoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | ESCC | View |
| None | Esophageal Cancer | View |
| None | Esophageal Neoplasms | View |
| None | Esophageal Neoplasms Malignant | View |
| None | Esophageal Squamous Cell Carcinoma | View |
| None | Neoplasms, Squamous Cell | View |
| None | Esophageal Diseases | View |
| None | Carcinoma, Squamous Cell | View |
| None | Gastrointestinal Diseases | View |
| None | Paclitaxel | View |
| None | Cisplatin | View |
| None | Fluorouracil | View |
| None | Antineoplastic Agents | View |
| None | Anti-PD-1 | View |
| None | Sintilimab | View |